Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • RNAarecrazy
    Junior Member
    • Jan 2014
    • 4

    #1

    MEDIP-seq: low unique reads

    Hi everyone, I mapped my medip-seq on mouse liver genome single end data with Bowtie 2 and only 10% of reads map to the mouse genome once, so only 1 million reads are "unique". Large proportion of reads either didn't map (12-17%) or mapped more than once (~75%). Here are the statistics below. My questions are:

    1) What could have caused this? Is this a biological or technical artifact?
    2) Is this data set still good?
    3) Should I only use the unique reads for downstream analyses?
    I appreciate all your help!! Thank you.

    Sample Total reads Aligned 0 times Aligned 1 time Aligned >1 times
    G109_M1 20872364 2912778 (13.96%) 1923779 (9.22%) 16035807 (76.83%)
    G109_M2 17193030 2771061 (16.12%) 1460643 (8.50%) 12961326 (75.39%)
    G109_M3 16982463 2786419 (16.41%) 1934671 (11.39%) 12261373 (72.20%)
    G109_M4 18290035 2242861 (12.26%) 1584429 (8.66%) 14462745 (79.07%)
    G109_M6 22931771 3452390 (15.06%) 2257734 (9.85%) 17221647 (75.10%)
    G109_M7 17036045 2166101 (12.71%) 1466390 (8.61%) 13403554 (78.68%)
    G109_M8 20080531 2736002 (13.63%) 1936385 (9.64%) 15408144 (76.73%)
    G109_M9 24497398 4164766 (17.00%) 2681647 (10.95%) 17650985 (72.05%)

Latest Articles

Collapse

  • SEQadmin2
    Beyond CRISPR/Cas9: Understand, Choose, and Use the Right Genome Editing Tool
    by SEQadmin2



    CRISPR/Cas9 sparked the gene editing revolution for both research and therapeutics.1 But this system still showed severe issues that limited its applications. The most prominent were the heavy reliance on PAM sequences, delivery limitations, double-stranded breaks that prompt unintended edits and cell death, and editing inefficiency (both in targeting and in knock-in reliability).

    Despite this, “CRISPR helped turn genome editing from a specialized technique into
    ...
    07-31-2026, 11:01 AM
  • SEQadmin2
    Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
    by SEQadmin2


    Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

    The systematic characterization of the human proteome has
    ...
    07-20-2026, 11:48 AM

ad_right_rmr

Collapse

News

Collapse

Topics Statistics Last Post
Started by SEQadmin2, Today, 10:05 AM
0 responses
8 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 08-13-2026, 12:22 PM
0 responses
32 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 08-11-2026, 10:35 AM
0 responses
24 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 08-06-2026, 07:41 AM
0 responses
38 views
0 reactions
Last Post SEQadmin2  
Working...